Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

AIMS: To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults without diabetes. MATERIALS AND METHODS: In this single‐centre, double‐blind trial, we randomized 50 obese adults with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Lundkvist, Per, Sjöström, C. David, Amini, Sam, Pereira, Maria J., Johnsson, Eva, Eriksson, Jan W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215525/
https://ncbi.nlm.nih.gov/pubmed/27550386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12779
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky